Abstract
Neuroleptic malignant syndrome (NMS) is a potentially fatal manifestation of antipsychotic use associated with symptoms that include mental status changes, muscle rigidity, fever and autonomic dysfunction. An occurrence of NMS with clozapine has been reported in the past but there are very few reports of successfully rechallenging the drug in individuals who have developed the syndrome. This case report discusses one of the few instances in literature where clozapine has been re-administered successfully to a patient without a reoccurrence of NMS. In conclusion, a rechallenge of clozapine after neuroleptic malignant syndrome can be done if care is taken to avoid concurrent use of lithium and other psychotropics, monitoring for NMS symptoms and titrating the dose upward slowly after a reasonable period of time.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amore M, Zazzeri N, Berardi D: Atypical neuroleptic malignant syndrome associated with Clozapine treatment. Neuropsychobiology 35(4):197–199, 1997
Manu P, Sarpal D, Muir O, Kane JM, Correll CU: When can patients with potentially life-threatening adverse effects be rechallenged with Clozapine? A systematic review of the published literature. Schizophrenia Research 134(2–3):180–186, 2012. doi:10.1016/j.schres.2011.10.014
Susman VL, Addonizio G: Recurrence of neuroleptic malignant syndrome. The Journal of Nervous and Mental Disease 176(4):234–241, 1988
Pope HG, Jr., Cole JO, Choras PT, Fulwiler CE: Apparent neuroleptic malignant syndrome with Clozapine and lithium. The Journal of Nervous and Mental Disease 174(8):493–495, 1986
Halman M, Goldbloom DS: Fluoxetine and neuroleptic malignant syndrome. Biological Psychiatry 28(6):518–251, 1990
Wilhelm K, Curtis J, Birkett V, Kenney-Herbert J: The clinical significance of serial creatine phosphokinase estimations in acute ward admissions. Australian and New Zealand Journal of Psychiatry 28(3):453–457, 1994
Tsai G, Crisostomo G, Rosenblatt ML, Stern TA: Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry 7(2):91–95, 1995
Huang TL: Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. Chang Gung Medical Journal 24(8):522–525, 2001
Anderson ES, Powers PS: Neuroleptic malignant syndrome associated with clozapine use. Journal of Clinical Psychiatry 52(3):102–104, 1991
Goates MG, Escobar JI: An apparent neuroleptic malignant syndrome without extrapyramidal symptoms upon initiation of clozapinetherapy: report of a case and results of a clozapine rechallenge. Journal of Clinical Psychopharmacology 12(2):139–140, 1992
Chatterton R, Cardy S, Schramm TM: Neuroleptic malignant syndrome and clozapine monotherapy. Australian and New Zealand Journal of Psychiatry 30(5):692–693, 1996
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anbalagan, E., Ithman, M. & Lauriello, J. Rechallenging Clozapine After Neuroleptic Malignant Syndrome. Psychiatr Q 85, 345–348 (2014). https://doi.org/10.1007/s11126-014-9291-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-014-9291-9